The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model

Natasa Jokic^{1,2*}, Jose-Luis Gonzalez de Aguilar^{1,2*}, Leda Dimou³, Shuo Lin⁴, Anissa Fergani^{1,2}, Markus A. Ruegg⁴, Martin E. Schwab³, Luc Dupuis^{1,2} & Jean-Philippe Loeffler^{1,2+}

¹Inserm, U692, Laboratoire de Signalisations Moléculaires et Neurodégénérescence, Strasbourg, France, ²Université Louis Pasteur, Faculté de Médecine, UMRS692, Strasbourg, France, ³Brain Research Institute, University of Zurich and Department of Biology, ETH Zurich, Zurich, Switzerland, and ⁴Biozentrum, University of Basel, Basel, Switzerland

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by motor neuron loss and muscle wasting. In muscles of ALS patients, Nogo-A—a protein known to inhibit axon regeneration—is ectopically expressed at levels that correlate with the severity of the clinical symptoms. We now show that the genetic ablation of Nogo-A extends survival and reduces muscle denervation in a mouse model of ALS. In turn, overexpression of Nogo-A in wild-type muscle fibres leads to shrinkage of the postsynapse and retraction of the presynaptic motor ending. This suggests that the expression of Nogo-A occurring early in ALS skeletal muscle could cause repulsion and destabilization of the motor nerve terminals, and subsequent dying back of the axons and motor neurons.

Keywords: amyotrophic lateral sclerosis; G86R mouse; neuromuscular junction; Nogo-A; skeletal muscle

EMBO reports (2006) 7, 1162–1167. doi:10.1038/sj.embor.7400826

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is the most common adult human motor neuron disease and causes motor neuron degeneration, progressive skeletal muscle atrophy, paralysis and death within 1–5 years of onset. Although most of the cases occur sporadically, approximately 10% of patients show an autosomal dominant pattern of inheritance and 10–20% of these are associated with missense mutations in the gene encoding Cu/Zn-superoxide dismutase 1 (SOD1), one of the main free radical

scavenging enzymes that protects cells against oxidative stress (Bruijn *et al*, 2004). The nature of the selective degeneration of motor neurons in ALS still remains elusive, but several studies postulate that the disease might begin at the distal axon and induce pathological changes earlier in the muscle than in the spinal cord (Frey *et al*, 2000; Fischer *et al*, 2004; Pun *et al*, 2006); however, the contribution of skeletal muscle fibres to initiating such a ‘dying back’ process has been largely undervalued.

Nogo-A was first identified as a high-molecular-weight membrane protein of spinal cord myelin, in part responsible for the non-permissive properties of the white matter in the central nervous system (Caroni & Schwab, 1988). At the molecular level, three distinct regions of Nogo-A have been shown to trigger neurite growth inhibition, growth cone collapse or inhibition of fibroblast spreading, which makes Nogo-A a key factor in restricting regeneration and repair of injured axons (Prinjha *et al*, 2000; GrandPre *et al*, 2002; Oertle *et al*, 2003). *In vivo* inactivation of Nogo-A by neutralizing antibodies or blockade of some of the components of its cognate signalling pathway leads to enhanced regeneration and improved functional recovery after spinal cord lesion (Li *et al*, 2004; Liebscher *et al*, 2005).

Previously, we have shown that the skeletal muscles of ALS-linked mutant Sod1 mice and patients with sporadic ALS express high amounts of Nogo-A (Dupuis *et al*, 2002). In addition, the levels of muscle Nogo-A in ALS patients are higher in atrophied slow-twitch fibres and correlate with the severity of motor impairment (Jokic *et al*, 2005). To extend our understanding of these findings, we investigated the effects of knocking out Nogo-A in ALS mice and evaluated the morphological changes at the neuromuscular junction (NMJ) after overexpressing Nogo-A in non-pathological muscle.

RESULTS

Genetic ablation of Nogo-A delays disease in ALS mice

We first determined Nogo-A expression during ALS pathology in *Sod1(G86R)* mice, a transgenic model that recapitulates many of the characteristics of the human disease (Ripps *et al*, 1995). In the soleus muscle, which in mice consists of slow-twitch fibres, Nogo-A upregulation occurred early in presymptomatic animals

¹Inserm, U692, Laboratoire de Signalisations Moléculaires et Neurodégénérescence, 11 rue Humann, F-67085 Strasbourg, France

²Université Louis Pasteur, Faculté de Médecine, UMRS692, 11 rue Humann, F-67085 Strasbourg, France

³Brain Research Institute, University of Zurich and Department of Biology, ETH Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland

⁴Biozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel, Switzerland

*These authors contributed equally to this work

+Corresponding author. Tel: +33 390 24 30 81; Fax: +33 390 24 30 65;

E-mail: loeffler@neurochem.u-strasbg.fr

and persisted after overt hindlimb paralysis (supplementary Fig 1A–C online). This expression accompanied the progressive decrease in muscle fibre size, also noticeable before the onset of apparent motor problems (supplementary Fig 1D online). To analyse the consequences of Nogo-A upregulation, we crossbred *Sod1(G86R)* mice with *Nogo-A*-knockout animals (Simonen et al, 2003). We checked that the soleus muscle of *G86R/Nogo-A^{-/-}* mice did not contain Nogo-A and assessed that Nogo-A ablation did not affect the expression of mutant Sod1 at both the messenger RNA and protein levels (supplementary Fig 2 online). We then recorded the survival of double transgenic mice and analysed several parameters that are characteristic of ALS pathology in symptomatic animals at comparable disease stages. This allowed us to recognize true protection effects rather than the age-related delay of symptoms. The mean survival times were 167 ± 11.2 days for *G86R/Nogo-A^{-/-}* mice ($n=16$) and 142 ± 6.4 days for the control littermates ($n=17$; $P=0.0456$, Mann–Whitney test), which accounts for a moderate but significant increase in lifespan as illustrated by the Kaplan–Meier curve representation (Fig 1A). Although the average levels of mutant Sod1 protein were almost identical in *G86R/Nogo-A^{+/+}* and *G86R/Nogo-A^{-/-}* mice (supplementary Fig 2G online), some interindividual variability could be observed (supplementary Fig 2F online). To rule out the possibility that Nogo-A ablation might promote lower mutant Sod1 expression and hence better survival, we analysed the influence of mutant Sod1 protein level variability on survival rates (supplementary Fig 4 online). Correlation analyses between these two parameters showed no significant differences, as determined by Spearman's correlation test ($P=0.4348$, $n=11$, *G86R/Nogo-A^{+/+}* mice; $P=0.1689$, $n=12$, *G86R/Nogo-A^{-/-}* mice). In addition, analysis of covariance was carried out in the *G86R/Nogo-A*-knockout group of animals, using survival as the dependent variable and mutant Sod1 protein levels as the explanatory variable. The probability corresponding to the F value (calculated by Fisher's F test) was 0.234 ($n=12$ mice), which means that the interindividual differences in the expression of mutant Sod1 have no significant influence on the survival of the animal.

To determine the number of large motor neurons in the lumbar spinal cord, we stained sections with toluidine blue and classified cells according to their cross-sectional area. In earlier studies (supplementary Fig 3 online), we found that cells with a cross-sectional area greater than $600 \mu\text{m}^2$ correspond to cells positive for the specific motor neuronal marker choline acetyltransferase, which corroborates our toluidine-blue-based estimates. In diseased *Sod1(G86R)* mice, we found a higher number of motor neurons in *Nogo-A^{-/-}* mice than in *Nogo-A^{+/+}* mice (Fig 1B). Furthermore, ubiquitin inclusions in the motor neuron cell bodies, which is a marker of cell stress typically detected in diseased animals, could not be seen in the double transgenic mice (Fig 1C). At the NMJ level, the increased expression of the acetylcholine receptor α -subunit mRNA—a typical marker of denervation in neuromuscular diseases (Duclert & Changeux, 1995)—was prevented in part in *G86R/Nogo-A^{-/-}* mice (Fig 1D). A similar attenuation was observed for the increase of mRNA encoding the muscle-specific receptor tyrosine kinase (MuSK; Fig 1D), which is a receptor kinase involved in acetylcholine receptor clustering (Bezakova & Ruegg, 2003) and the expression of which is coordinated with that of the acetylcholine receptor on denervation (Valenzuela et al, 1995). We also carried out immunoprecipitation

Fig 1 | Genetic ablation of Nogo-A in *Sod1(G86R)* mice. (A) Cumulative probability of survival of *G86R/Nogo-A^{+/+}* and *G86R/Nogo-A^{-/-}* mice ($P=0.04$, $n=16$ –17 mice, log-rank test). (B) Cell counts in the ventral horns of the lumbar spinal cord of *G86R/Nogo-A^{+/+}* and *G86R/Nogo-A^{-/-}* mice. Toluidine-blue-stained cells were divided into two groups of 300 – $600 \mu\text{m}^2$ and $>600 \mu\text{m}^2$, the latter clearly representing motor neurons. No differences were observed in the number of cells between non-Cu/Zn-superoxide dismutase 1 (*Sod1(G86R)*) *Nogo-A*-knockout and wild-type mice (data not shown; $*P<0.05$ versus corresponding $+/+$, $n=3$ mice, Student's t -test). (C) Ubiquitin immunoreactivity in large motor neurons (cross-sectional area $>600 \mu\text{m}^2$; arrowheads) of the lumbar spinal cord from *G86R/Nogo-A^{+/+}* and *G86R/Nogo-A^{-/-}* mice. Scale bar, $30 \mu\text{m}$. (D) Messenger RNA levels of acetylcholine receptor α -subunit (AChR α) and muscle-specific receptor tyrosine kinase (MuSK) in the soleus muscle of wild-type (WT; open bars) and *Sod1(G86R)* mice (filled bars) containing ($+/+$) or not containing ($-/-$) Nogo-A ($***P<0.001$ versus wild type, $*P<0.05$ versus $+/+$, $n=4$ –5 mice, analysis of variance followed by Tukey's test). (E) Levels of MuSK protein as determined by western blot of immunoprecipitated MuSK from muscle extracts of *Sod1(G86R)* mice containing ($+/+$) or not containing ($-/-$) Nogo-A. MW, molecular weight markers. In all cases, symptomatic animals reached the end point of the disease. Sod1, Cu/Zn-superoxide dismutase 1.

experiments with whole hindlimb muscles to detect MuSK protein levels, and found that the immunoreactivity specific for MuSK protein observed in the immunoprecipitates from *G86R/Nogo-A^{+/+}* mice had disappeared in *G86R/Nogo-A^{-/-}* mice (Fig 1E). These data clearly show that Nogo-A ablation in ALS mice not only prevented the increase in *mus* gene expression, characteristically observed in these animals, but also reduced the levels of MuSK protein, thereby confirming the attenuated denervation of muscles. Therefore, although the overall effect of Nogo-A deletion on the survival of *G86R* mice was moderate, these findings show

a protective action for motor neurons at both the cell body and the endplate levels.

Nogo-A overexpression in muscle affects NMJ

The neuroprotective effects of Nogo-A ablation and the increase of Nogo-A in diseased ALS muscle indicate that high levels of ectopic Nogo-A in adult skeletal muscle might influence the NMJ and thereby induce retrograde axon pathology. We tested this hypothesis by analysing the morphology of NMJs *in vivo* in the soleus muscle of wild-type animals on transfection of muscle fibres by electroporation with an expression plasmid encoding Nogo-A fused to a Myc tag. To allow independent identification of Nogo-A-transfected muscle fibres, a plasmid encoding green fluorescent protein (GFP) fused to a nuclear localization signal (NLS-GFP) was co-transfected. First, we examined the expression of Nogo-A in the transfected muscle fibres by staining the soleus muscle with antibodies directed against the Myc tag. As shown in Fig 2A,B, Nogo-A was detected 2 weeks after electroporation in muscle fibres that were also positive for NLS-GFP. This confirms that our experimental design is well suited for the overexpression of Nogo-A in muscle. To examine the influence of Nogo-A overexpression on the morphology of the NMJs, we used *Thy-1* (T-cell antigen)/yellow fluorescent protein mice (Feng *et al*, 2000), which allow direct identification of presynaptic nerve terminals. Postsynaptic acetylcholine receptors were visualized with rhodamine-conjugated α -bungarotoxin. NMJs were examined only 6 weeks after electroporation because we had already observed that changes in morphology on perturbation of MuSK, which is required for the formation of the NMJ (DeChiara *et al*, 1996), require 4–6 weeks (Kong *et al*, 2004). In all experiments, NMJs located on transfected (that is, NLS-GFP-positive) muscle fibres were analysed. As shown in Fig 2C, NMJs on muscle fibres transfected with empty vector (control) looked normal. By contrast, NMJs on muscle fibres expressing Nogo-A were often smaller (Fig 2D), postsynaptic structures were fragmented and the presynaptic nerve terminal only partly occupied the postsynaptic region (Fig 2E). In a few cases, the presynaptic nerve terminal had retracted entirely from the fragmented postsynaptic region (Fig 2F). The effect of Nogo-A on both the pre- and postsynaptic sides was quantified using the groups described above (Table 1). Although most NMJs looked normal in control muscle, approximately 90% of the NMJs located on Nogo-A-expressing muscle fibres had an aberrant structure.

We also quantified the effect of Nogo-A on the size of the postsynaptic apparatus, by measuring the area stained with α -bungarotoxin in flat-mounted muscle preparations. Postsynapses on neighbouring, non-transfected muscle fibres acted as controls. Postsynapses on muscle fibres transfected with empty vector (control) occupied an area of $400 \pm 60 \mu\text{m}^2$ ($n = 4$ mice; a total of 11 NMJs examined), whereas those located on non-transfected muscle fibres in the same muscle were $469 \pm 66 \mu\text{m}^2$ ($n = 3$ mice; six NMJs). Thus, there is no significant difference between transfected and non-transfected muscle fibres in control muscles. By contrast, postsynapses in muscle fibres transfected with the expression construct for Nogo-A were only $241 \pm 15 \mu\text{m}^2$ ($n = 6$ mice; 47 NMJs). Similar to control mice, postsynapses on non-transfected muscle fibres in the same muscles occupied an average area of $452 \pm 35 \mu\text{m}^2$ ($n = 4$ mice; 11 NMJs). Thus, the postsynaptic regions of the muscle fibres that overexpress Nogo-A

are significantly ($P = 0.005$) smaller than those in control muscle fibres or neighbouring, non-transfected muscle fibres. Our data are consistent with the idea that increased levels of Nogo-A destabilize the NMJ and eventually lead to retraction of the nerve terminal.

DISCUSSION

Several studies postulate that motor neuron death in ALS is preceded by pathological changes and degeneration of the motor axons and their nerve terminals (Ferri *et al*, 2003; Kieran *et al*, 2005). On the basis of our present findings, we propose that the high expression of Nogo-A in ALS muscle might affect the integrity of the NMJ, leading to its destabilization and retraction of the nerve terminal. This process could trigger a progressive 'dying back' mechanism that ultimately leads to motor neuron degeneration. As muscle Nogo-A upregulation is observed in both mutant *Sod1* mice and patients with sporadic ALS (Dupuis *et al*, 2002; Jokic *et al*, 2005), the deleterious effect of muscle Nogo-A on the NMJ might represent a common pathological event and a potential therapeutic target for the maintenance of the neuromuscular connections. Blocking the ability of Nogo-A to inhibit neurite outgrowth promotes axonal sprouting and functional recovery after spinal cord lesion (Li *et al*, 2004; Liebscher *et al*, 2005), which suggests that such an approach could be applicable to alleviate motor impairment in ALS.

Our findings show that specific transcriptional changes in skeletal muscle fibres, that is, increased Nogo-A expression, might hamper the dialogue between motor neurons and muscles. It is now accepted that motor neurons are not the only sites at which mutant *Sod1* toxicity acts primarily to trigger ALS (Lino *et al*, 2002; Clement *et al*, 2003). Rather, the disease results from toxicity to the whole neuromuscular unit, as supported by recent studies (Wang *et al*, 2005). Thus, neurogenic injury and also other mechanisms of muscle origin, as discussed here, work together to cause the characteristic phenotype of the diseased NMJ in ALS (Fischer *et al*, 2004). Far from having a passive role in the establishment of neuromuscular connections, muscle-intrinsic signals can initiate the differentiation of neuromuscular synapses independently of neurogenic stimulation (Lin *et al*, 2001) and regulate motor neuron excitability (Nick & Ribera, 2000; Nakanishi *et al*, 2005). In ALS mice, the protective action for motor neurons offered by the intramuscular delivery of retrogradely transported active molecules might also imply benefit to muscle fibres (Kaspar *et al*, 2003; Azzouz *et al*, 2004; Miller *et al*, 2005). Indeed, the expression of a locally acting isoform of insulin-like growth factor 1 in only muscles is sufficient to maintain NMJ integrity, delay motor neuron death and prolong the lifespan of mutant *Sod1* mice (Dobrowolny *et al*, 2005). Finally, we recently reported that the skeletal muscles of ALS mice show an unexpectedly augmented metabolic rate before overt motor symptoms appear (Dupuis *et al*, 2004), which further supports the involvement of non-neuronal mechanisms during the course of the disease. Compensating for such a hypermetabolic trait with a highly energetic diet reduces muscle denervation, offers neuroprotection and increases survival (Dupuis *et al*, 2004).

In summary, we provide new evidence for the active role of skeletal muscle in the maintenance of motor neuron function and suggest a role of Nogo-A in synapse integrity and stabilization. The suppression of Nogo-A increased the number of healthy motor neurons in end-stage ALS mice and moderately prolonged their

Fig 2 | Overexpression of Nogo-A in muscle causes the disassembly of the neuromuscular junction. Electroporation of the soleus muscle with expression constructs for Nogo-A and nuclear-localized green fluorescent protein (GFP) results in muscle fibres that express high levels of Nogo-A (red) and GFP (green) after 2 weeks. (A) Whole-mount and (B) cross-section of the soleus muscle. Representative pictures of neuromuscular junctions (NMJs), 6 weeks after electroporation of empty vector (control; C) or Nogo-A expression constructs (D–F). The postsynaptic apparatus was visualized by rhodamine-labelled α -bungarotoxin (acetylcholine receptor; red in merge). Presynaptic nerve terminals were labelled by yellow fluorescent protein (YFP; green in merge) and transfected muscle fibres by nuclear localization signal–GFP (GFP, green in merge). For clarification, GFP-positive myonuclei are indicated by arrowheads. In control transfections, both pre- and postsynaptic structures look normal (C). By contrast, overexpression of Nogo-A often results in smaller NMJs (D) and fragmentation of the postsynaptic structure including partial (E; hollow arrows) or total (F; asterisks) retraction of the presynaptic nerve terminal. Scale bar, 25 μ m.

Table 1|Quantification of morphological changes at the neuromuscular junction after overexpression of Nogo-A in the soleus muscle

Experiment	Side of NMJ	Total number of NMJs*	Normal‡	Abnormal‡		
				Smaller	Fragmented	Lost
Control	Postsynaptic	20 (3)	18 (90)	1 (5)	1 (5)	0 (0)
	Presynaptic	8 (3)	7 (87.5)	1 (12.5)	0 (0)	0 (0)
Nogo-A	Postsynaptic	47 (6)	5 (11)	25 (53)	12 (25)	5 (11)
	Presynaptic	45 (4)	7 (17)	19 (45)	12 (29)	4 (9)

The different classes for pre- and postsynaptic structures are as described in Fig 2. NMJ, neuromuscular junction.
*The total number of NMJs is shown, with the number of mice in parentheses.
‡The data represent the total number of NMJs with a particular phenotype and the relative percentages are in parentheses. Note that in cases in which the phenotype was intermediate between different classes, the less severe class was chosen.

lives. Much effort must now be concentrated on deciphering the molecular mechanisms underlying these effects.

METHODS

Western blot, immunoprecipitation, immunohistochemistry, morphometry, real-time reverse transcription-PCR and analysis of transgene copy number are described in the supplementary information online.

Mice. Transgenic FVB/N males with the G86R murine Sod1 mutation were obtained from our animal facility. Sod1(G86R) mice were crossed with C57Bl/6 wild-type or Nogo-A-deficient mice. The resulting F1 generation animals were crossed again with new C57Bl/6 wild-type and Nogo-A-knockout mice; mice that were homozygous or wild type for the Nogo-A deficiency and heterozygous for the Sod1 mutation were obtained. Genotyping was carried out as described by Ripps et al (1995) and Simonen et al (2003). Details are given in the supplementary information online.

In vivo muscle transfection. Ectopic expression of Nogo-A in the soleus muscle was obtained by in vivo transfection of a pcDNA3/ Myc-tagged/Nogo-A plasmid, previously described by Prinjha et al (2000). Identification of transfected fibres was achieved by co-transfection of a pGFP-S6 construct encoding a GFP that is targeted to the nucleus (Jones et al, 1999). The procedure for transfection has been described previously (Kong et al, 2004; for details, see supplementary information online).

Supplementary information is available at EMBO reports online (<http://www.emboreports.org>).

ACKNOWLEDGEMENTS

We thank Mrs A. Picchinenna and Miss M.J. Ruivo for excellent technical assistance. This work was supported by grants from the French organizations Association Française contre les Myopathies (AFM), Biovalley, Association pour la Recherche sur la Sclérose Latérale Amyotrophique (ARS) and Association pour la Recherche contre les Maladies Neurodégénératives (AREMANE) to J.P.-L.; the Swiss National Science Foundation (SNSF) and the National Center of Competence in Research (NCCR) on Neural Plasticity and Repair to M.E.S.; and the SNSF and the Swiss Foundation for Research on Muscle Diseases to M.A.R. N.J. was the recipient of a grant from Association Française contre les Myopathies (AFM). A.F. is the recipient of a grant from Région Alsace and Association pour L'Etude de la Culture d'Embryons et des Thérapeutiques des Maladies du Système Nerveux (ACE; France).

REFERENCES

Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. *Nature* **429**: 413–417
Bezakova G, Ruegg MA (2003) New insights into the roles of agrin. *Nat Rev Mol Cell Biol* **4**: 295–308
Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. *Annu Rev Neurosci* **27**: 723–749
Caroni P, Schwab ME (1988) Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. *Neuron* **1**: 85–96
Clement AM et al (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. *Science* **302**: 113–117
DeChiara TM et al (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. *Cell* **85**: 501–512
Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, Molinaro M, Rosenthal N, Musaro A (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. *J Cell Biol* **168**: 193–199
Duclert A, Changeux JP (1995) Acetylcholine receptor gene expression at the developing neuromuscular junction. *Physiol Rev* **75**: 339–368
Dupuis L et al (2002) Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. *Neurobiol Dis* **10**: 358–365
Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. *Proc Natl Acad Sci USA* **101**: 11159–11164
Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR (2000) Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. *Neuron* **28**: 41–51
Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC (2003) Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. *Curr Biol* **13**: 669–673
Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. *Exp Neurol* **185**: 232–240
Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P (2000) Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. *J Neurosci* **20**: 2534–2542
GrandPre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal regeneration. *Nature* **417**: 547–551
Jokic N et al (2005) Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. *Ann Neurol* **57**: 553–556
Jones G, Moore C, Hashemolhosseini S, Brenner HR (1999) Constitutively active MuSK is clustered in the absence of agrin and induces ectopic postsynaptic-like membranes in skeletal muscle fibers. *J Neurosci* **19**: 3376–3383

- Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. *Science* **301**: 839–842
- Kieran D, Hafezparast M, Bohnert S, Dick JR, Martin J, Schiavo G, Fisher EM, Greensmith L (2005) A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. *J Cell Biol* **169**: 561–567
- Kong XC, Barzaghi P, Ruegg MA (2004) Inhibition of synapse assembly in mammalian muscle *in vivo* by RNA interference. *EMBO Rep* **5**: 183–188
- Li S *et al* (2004) Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. *J Neurosci* **24**: 10511–10520
- Liebscher T *et al* (2005) Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. *Ann Neurol* **58**: 706–719
- Lin W, Burgess RW, Dominguez B, Pfaff SL, Sanes JR, Lee KF (2001) Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse. *Nature* **410**: 1057–1064
- Lino MM, Schneider C, Caroni P (2002) Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. *J Neurosci* **22**: 4825–4832
- Miller TM, Kaspar BK, Kops GJ, Yamanaka K, Christian LJ, Gage FH, Cleveland DW (2005) Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. *Ann Neurol* **57**: 773–776
- Nakanishi ST, Cope YC, Rich MM, Carrasco DI, Pinter MJ (2005) Regulation of motoneuron excitability via motor endplate acetylcholine receptor activation. *J Neurosci* **25**: 2226–2232
- Nick TA, Ribera AB (2000) Synaptic activity modulates presynaptic excitability. *Nat Neurosci* **3**: 142–149
- Oertle T *et al* (2003) Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. *J Neurosci* **23**: 5393–5406
- Prinjha R, Moore SE, Vinson M, Blake S, Morrow R, Christie G, Michalovich D, Simmons DL, Walsh FS (2000) Inhibitor of neurite outgrowth in humans. *Nature* **403**: 383–384
- Pun S, Santos AF, Saxena S, Xu L, Caroni P (2006) Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. *Nat Neurosci* **9**: 408–419
- Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* **92**: 689–693
- Simonen M, Pedersen V, Weinmann O, Schnell L, Buss A, Ledermann B, Christ F, Sansig G, van der Putten H, Schwab ME (2003) Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. *Neuron* **38**: 201–211
- Valenzuela DM *et al* (1995) Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. *Neuron* **15**: 573–584
- Wang J, Xu G, Slunt HH, Gonzales V, Coonfield M, Fromholt D, Copeland NG, Jenkins NA, Borchelt DR (2005) Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. *Neurobiol Dis* **20**: 943–952